Company: INTS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001567264-25-000039
Chunk: 21

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
U 2024-03 will have on its financial statement disclosures.

Note 4.    Cash and Cash Equivalents

Cash and cash equivalents consisted of the following (in thousands):March 31,2025December 31,2024Savings and checking accounts at major U.S. financial institutions$94 $428 U.S. Treasury securities money market fund835 2,162 Total$929 $2,590 

Note 5.    Prepaid Expenses and Other Current Assets

Prepaid expenses consisted of the following (in thousands):March 31,2025December 31,2024Prepaid insurance$262 $421 Prepaid research and development costs219 239 Prepaid other241 113 Total$722 $773 

7

Note 6.    Accrued Expenses

Accrued expenses consisted of the following (in thousands):March 31,2025December 31,2024Accrued research and development costs$910 $374 Accrued employee compensation-related expenses— 56 Accrued other104 78 Total$1,014 $508 

Note 7.    Stockholders’ Equity 

At The Market Offering AgreementOn July 3, 2024, the Company entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may sell and issue, from time to time, up to $15.0 million of shares of its common stock (the “Shares”) through Wainwright as the Company’s sales agent (the “ATM Offering”). The Company has no obligation to sell any of the Shares and may at any time suspend offers under the Sales Agreement or terminate the Sales Agreement pursuant to its terms. On November 21, 2024, the Company filed a prospectus supplement to reduce the maximum the Company may sell and issue under the Sales Agreement to $7.0 million of its Shares, not including the Shares previously sold under the Sales Agreement. For the three months ended March 31, 2025, the Company issued 141,996 shares of common stock under the ATM Agreement for net proceeds of $0.3 million. Since inception, we have issued 193,816 shares of common stock under the ATM Agreement for net proceeds of $0.5 million.Registered direct offering

On November 21, 2024,